PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interaction Between Tegoprazan and Novel Oral Anticoagulants (NOACs) After Multiple Oral Dosing in Healthy Volunteers

This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Edoxaban 60mg; Drug: Tegoprazan 50mg; Drug: Apixaban 5mg; Drug: Rivaroxaban 20mg

Detailed Description

A randomized, open-label, multiple-dose, two-arm, two-period crossover study

[Cohort 1] To evaluate the effects of combination therapy of tegoprazan and edoxaban on the pharmacokinetic and pharmacodynamic properties of edoxaban in healthy adults.

[Cohort 2] To evaluate the effects of combination therapy of tegoprazan and apixaban on the pharmacokinetic and pharmacodynamic properties of apixaban in healthy adults.

[Cohort 3] To evaluate the effects of combination therapy of tegoprazan and rivaroxaban on the pharmacokinetic and pharmacodynamic properties of rivaroxaban in healthy adults.

• Study Type: Interventional
• Enrollment (Actual): 87
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Ha-neul Jeong; Phone Number: +82-2-6477-0291; Email: hn.jeong@inno-n.com

Study Locations

• Korea, Republic of
  • Jeonju, Korea, Republic of
    • Jeonbuk National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 54 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy adults aged ≥ 19 years to < 55 years at the time of screening

2. Those with body weight ≥ 45 kg (but ≥ 60 kg for cohort 1 and cohort 2) and body mass index (BMI) in the range of 19.0 kg/m2 to 27.0 kg/m2 at the time of screening

   ☞ BMI = weight (kg) / height (m)2

3. Those who have neither congenital/chronic disease (within recent 3 years) nor pathological symptoms/findings as a result of medical examination
4. Those determined to be eligible for this study based on the findings of screening such as clinical laboratory tests (hematological test, blood chemistry test, blood coagulation test, urinalysis, test for viruses/bacteria, etc.), vital signs, and electrocardiogram (ECG) which are performed by the investigator according to the properties of medicines
5. Those who are fully informed of study purpose, procedures, etc., voluntarily decide to participate in this study, and sign an informed consent form (ICF) approved by the Institutional Review Board (IRB) of Jeonbuk National University Hospital, prior to participation in the study
6. Those with a capability/willingness to participate throughout the study

Exclusion Criteria:

1. Medical history of clinically significant blood, renal, endocrine, respiratory, gastrointestinal (peptic ulcer, etc.), urinary, cardiovascular, hepatic, psychiatric, neurological or immune disease (but except for history of simple dental treatment such as tartar, impacted teeth, and third molar teeth) or evidence thereof
2. Previous history of gastrointestinal disease (except for esophageal disease such as esophageal achalasia or esophageal stricture, inflammatory bowel disease (Crohn's disease, ulcerative colitis)) or surgery (not including simple appendectomy, hernia surgery, tooth extraction, etc.) which may affect drug absorption

3. Following findings of clinical laboratory tests:

   ☞ ALT or AST value > twice the upper limit of normal (ULN)

4. History of periodic alcohol consumption exceeding 210 g/week within 6 months prior to screening (beer (5%) 1 glass (250 mL) = 10 g, soju (20%) 1 glass (50 mL) = 8 g, wine (12%) 1 glass (125 mL) = 12 g)
5. Administration of another investigational product within 6 months prior to the first dose of the investigational product
6. History of serious alcohol or drug misuse and abuse within 1 year prior to screening
7. Administration of drugs known to markedly induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose of the investigational product
8. History of smoked cigarettes ≥ 20 cigarettes/day within 6 months prior to screening
9. Administration of a prescription or non-prescription drug within 10 days prior to the first dose of the investigational product
10. Whole blood donation within 2 months prior to the first dose of the investigational product or apheresis donation within 1 month prior to the first dose of the investigational product
11. Those who may be put at an increased risk due to the adminisration of the investigational product and study participation or have a severe acute/chronic medical or mental condition which may interfere with the interpretation of study results
12. Patients with hypersensitivity to tegoprazan, edoxaban, apixaban, rivaroxaban, etc. (e.g., asthma, acute rhinitis, nasal polyp, angioedema, urticaria, allergic reactions, etc.)
13. Patients with a clinically significant bleeding
14. Patients with hemostatic disorder and hepatic disease related to a clinically significant risk of bleeding
15. Severe hepatic impairment
16. Renal impairment (eGFR <60 ml/min/1.73m2)
17. Hereditary problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
18. Pregnant/breast-feeding women

19. Those who cannot use medically acceptable contraceptive methods throughout the study

    ▶ Medically acceptable contraceptive methods

    • Use of intrauterine device (IUD) showing a demonstrated pregnancy failure rate
    • Combined use of barrier contraceptive method (for male or female) and spermicide
    • Use of vasectomy, tubectomy/tubal ligation, or hysterectomy
20. Those who are not eligible for the study in the judgment of the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Edoxaban 60mg; Multiple dosing of edoxaban alone once daily for 5 days	Drug: Edoxaban 60mg; Oral administration of one tablet of edoxaban 60 mg once daily; Other Names: Lixiana Tab. 60mg
Experimental: Edoxaban 60mg + Tegoprazan 50mg; Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days	Drug: Edoxaban 60mg; Oral administration of one tablet of edoxaban 60 mg once daily; Other Names: Lixiana Tab. 60mg; Drug: Tegoprazan 50mg; Oral administration of one tablet of tegoprazan 50 mg once daily; Other Names: K-CAB Tab. 50 mg
Experimental: Apixaban 5mg; Multiple dosing of apixaban alone twice daily for 5 days	Drug: Apixaban 5mg; Oral administration of one tablet of apixaban 5 mg twice daily; Other Names: Eliquis Tab. 5 mg
Experimental: Apixaban 5mg + Tegoprazan 50mg; Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days	Drug: Tegoprazan 50mg; Oral administration of one tablet of tegoprazan 50 mg once daily; Other Names: K-CAB Tab. 50 mg; Drug: Apixaban 5mg; Oral administration of one tablet of apixaban 5 mg twice daily; Other Names: Eliquis Tab. 5 mg
Experimental: Rivaroxaban 20mg; Multiple dosing of rivaroxaban alone once daily for 5 days	Drug: Rivaroxaban 20mg; Oral administration of one tablet of rivaroxaban 20 mg once daily; Other Names: Xarelto Tab. 20 mg
Experimental: Rivaroxaban 20mg + Tegoprazan 50mg; Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days	Drug: Tegoprazan 50mg; Oral administration of one tablet of tegoprazan 50 mg once daily; Other Names: K-CAB Tab. 50 mg; Drug: Rivaroxaban 20mg; Oral administration of one tablet of rivaroxaban 20 mg once daily; Other Names: Xarelto Tab. 20 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCτ and Css,max of edoxaban	Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of edoxaban	Pre-dose(0 hour) on 1D, 3D, and 4D for each period; pre-dose(0 hour) up to 48 hours after treatment on 5D for each period
AUCτ and Css,max of apixaban	Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of apixaban	Pre-dose (0 hour) in the morning on 1D and in the morning and afternoon on 4D for each period; pre-dose(0 hour) in the morning up to 48 hours after treatment on 5D for each period
AUCτ and Css,max of rivaroxaban	Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of rivaroxaban	Pre-dose (0 hour) on 1D, 3D, and 4D for each period; pre-dose(0 hour) up to 48 hours after treatment on 5D for each period
AUECτ and Emax of Anti-Factor Xa activity, PT, aPTT, and Prothrombin (INR)	Area under the effect-time curve over the dosing interval (τ) at steady state and maximum effect of Anti-Factor Xa activity, PT, aPTT, and Prothrombin (INR)	Pre-dose (0 hour) up to 24 hours after treatment on 5D for each period

Collaborators and Investigators

• Sponsor: HK inno.N Corporation
• Investigators: Principal Investigator: Min-Gul Kim, Clinical Pharmacology Center, Jeonbuk National University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2023
• Primary Completion (Actual): July 17, 2023
• Study Completion (Actual): July 24, 2023

Study Registration Dates

• First Submitted: February 2, 2023
• First Submitted That Met QC Criteria: February 2, 2023
• First Posted (Actual): February 10, 2023

Study Record Updates

• Last Update Posted (Estimated): December 11, 2023
• Last Update Submitted That Met QC Criteria: December 7, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protease Inhibitors; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Anticoagulants; Rivaroxaban; Apixaban; Edoxaban
• Other Study ID Numbers: IN_APA_121

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No